Bond Biosciences develops first-in-class non-absorbed oral therapeutics that bind excess dietary iron in the gastrointestinal tract to prevent iron overload in patients with Hereditary Hemochromatosis. Their lead product, BBI-001, offers a safe and effective alternative to phlebotomy, addressing the serious health risks associated with unmanaged iron levels, such as liver disease and diabetes.
Funding
$15.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CPFounders
Product
Problem
Hereditary Hemochromatosis, characterized by excessive iron absorption, lacks effective FDA-approved therapies, leading to serious health risks like liver disease, heart problems, and diabetes. Current treatments, such as phlebotomy, are often difficult, painful, and suffer from low long-term adherence.
Solution
Bond Biosciences is developing BBI-001, a first-in-class, non-absorbed oral therapeutic designed to bind excess dietary iron in the gastrointestinal (GI) tract. By inhibiting iron absorption, BBI-001 aims to prevent the potentially serious consequences of unmanaged iron overload resulting from hemochromatosis. The therapeutic is designed to be a safe, convenient, and effective alternative to existing treatments. Pre-clinical animal models have demonstrated the effectiveness of BBI-001, and the company is progressing towards clinical proof of concept in humans.
Target Audience
The primary target audience includes individuals diagnosed with Hereditary Hemochromatosis who require a safe, convenient, and effective alternative to phlebotomy for managing iron overload.
Features
- Non-absorbed polymer designed to selectively bind iron in the GI tract.
- Oral administration for convenient self-administration.
- Designed to prevent iron overload and associated complications.
- Demonstrated efficacy in pre-clinical animal models.
- Potential for application to other ion-related diseases.